Hemostatic abnormalities in endocrine and metabolic disorders

European Journal of Endocrinology

Volumn 162, Issue 3, 2010, Pages 439-451

  Franchini, Massimo ^a   Lippi, Giuseppe ^a   Manzato, Franco ^b   Vescovi, Pier Paolo ^b   Targher, Giovanni ^c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACROMEGALY; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; CUSHING SYNDROME; ENDOCRINE DISEASE; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERCOAGULABILITY; HYPERTHYROIDISM; HYPOPHYSIS ADENOMA; HYPOTHYROIDISM; METABOLIC DISORDER; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROLACTINOMA; REVIEW;

BLOOD COAGULATION; ENDOCRINE SYSTEM DISEASES; HEMORRHAGE; HUMANS; METABOLIC DISEASES; THROMBOSIS;

EID: 77149140109     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0958     Document Type: Review

References (150)

1. Squizzato A, Gerdes VE, Ageno W & Büller HR. The coagulation system in endocrine disorders: a narrative review. Internal and Emergency Medicine 2007 2 76-83.
2. Furie B & Furie BC. Mechanisms of thrombus formation. New England Journal of Medicine 2008 359 938-949.
3. Squizzato A, Romualdi E, Büller HR & Gerdes VE. Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. Journal of Clinical Endocrinology and Metabolism 2007 92 2415-2420.
4. Franchini M. Hemostasis and thyroid diseases revisited. Journal of Endocrinological Investigation 2004 27 886-892.
5. Franchini M, Montagnana M, Manzato F & Vescovi PP. Thyroid dysfunction and hemostasis: an issue still unresolved. Seminars in Thrombosis and Hemostasis 2009 35 288-294.
6. Erem C. Coagulation and fibrinolysis in thyroid dysfunction. Endocrine 2009 36 110-118.
7. Ford HC & Carter JM. Haemostasis in hypothyroidism. Postgraduate Medical Journal 1990 66 280-284.
8. Erem C, Kavgaci H, Ersöz H, Hacihasanoglu A, Ukinç K, Karti SS, Deger O & Telatari M. Blood coagulation and fibrinolytic activity in hypothyroidism. International Journal of Clinical Practice 2003 57 78-81.
9. Hofbauer LC & Heufelder AE. Coagulation disorders in thyroid diseases. European Journal of Endocrinology 1997 136 1-7.
10. Marongiu F, Cauli C & Mariotti S. Thyroid, hemostasis and thrombosis. Journal of Endocrinological Investigation 2004 27 1065-1071.
11. Dalton RG, Dewar MS, Savidge GF, Kernoff PB, Matthews KB, Greaves M & Preston FE. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1987 1 1007-1009.
12. Blesing NE, Hambley H & McDonald GA. Acquired von Willebrand's disease and hypothyroidism: report of a case presenting with menorrhagia. Postgraduate Medical Journal 1990 66 474-476.
13. Thornton JG, Parapia LA & Minford AMB. Hypothyroidism and von Willebrand's disease. Lancet 1987 1 1314-1315.
14. Nitu-Whalley IC & Lee CA. Acquired von Willebrand syndrome - report of 10 cases and review of the literature. Haemophilia 1999 5 318-326.
15. Michiels JJ, Schroyens W, Berneman Z & van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clinical and Applied Thrombosis/Hemostasis 2001 7 113-115.
16. Attivissimo LA, Lichtman SM & Klein I. Acquired von Willebrand's syndrome causing a hemorrhagic diathesis in a patient with hypothyroidism. Thyroid 1995 5 399-401.
17. Aylesworth C, Smallridge RC, Rick ME & Alving BM. Acquired von Willebrand's disease: a rare manifestation of postpartum thyroiditis. American Journal of Hematology 1995 50 217-219.
18. Tjan-Heijnen VC, Harthoorn-Lasthuizen EJ, Kurstjens RM & Koolen MI. A patient with postpartum primary hypothyroidism and acquired von Willebrand's disease. Netherlands Journal of Medicine 1994 44 91-94.
19. Franchini M, de Gironcoli M, Lippi G, Manzato F, Brazzarola P, Bottura D, Aprili G & Gandini G. Efficacy of desmopressin as surgical prophylaxis in patients with acquired von Willebrand disease undergoing thyroid surgery. Haemophilia 2002 8 142-144.
20. Franchini M, Zugni C, Veneri D, Gandini G, Lippi G, Manzato F & Brazzarola P. High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery. Haematologica 2004 89 1341-1346.
21. Franchini M, Veneri D & Lippi G. Analysis of thyroid hormone status in 131 consecutive individuals with low von Willebrand factor levels. Thrombosis and Haemostasis 2005 93 392-393.
22. Bruggers CS, McElligott K & Rallison ML. Acquired von Willebrand disease in twins with autoimmune hypothyroidism: response to desmopressin and L-thyroxine therapy. Journal of Pediatrics 1994 125 911-913.
23. Myrup B, Bregengå rd C & Faber J. Primary haemostasis and thyroid disease. Journal of Internal Medicine 1995 238 59-63.
24. Zeigler ZR, Hasiba U, Lewis JH, Vagnucci AH, West VA & Bezek EA. Hemostatic defects in response to aspirin challenge in hypothyroidism. American Journal of Hematology 1986 17 209-215.
25. Edson JR, Fecher DR & Doe RP. Low platelet adhesiveness and other abnormalities in hypothyroidism. Annals of Internal Medicine 1975 82 342-346.
26. Palareti G, Biagi G, Legnani C, Bianchi D, Serra D, Savini R & Coccheri S. Association of reduced factor VIII with impaired platelet reactivity to adrenalin and collagen after total thyroidectomy. Thrombosis and Haemostasis 1989 62 1053-1056.
27. Egeberg BO. Influence of thyroid function on the blood clotting system. Scandinavian Journal of Clinical and Laboratory Investigation 1963 15 1-7.
28. Simone JV, Abildgaard CF & Schulman I. Blood coagulation in thyroid dysfunction. New England Journal of Medicine 1965 273 1057-1061.
29. Rogers JS, Shane SR & Jencks FS. Factor VIII activity and thyroid function. Annals of Internal Medicine 1982 97 713-716.
30. Nordoy A, Vikmo H & Berntsen H. Haemostatic and lipid abnormalities in hypothyroidism. Scandinavian Journal of Haematology 1976 16 154-160.
31. Gullu S, Sav H & Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. European Journal of Endocrinology 2005 152 355-361.
32. Chadarevian R, Bruckert E, Ankri A, Beucler I, Giral P & Turpin G. Relationship between thyroid hormones and plasma D-dimer levels. Thrombosis and Haemostasis 1998 79 99-103.
33. Müller B, Tsakiris DA, Roth CB, Guglielmetti M, Staub JJ & Marbet GA. Haemostatic profile in hypothyroidism as potential risk for vascular or thrombotic disease. European Journal of Clinical Investigation 2001 31 131-137.
34. Meiklejohn DJ & Watson HG. Acquired haemophilia in association with organ-specific autoimmune disease. Haemophilia 2001 7 523-525.
35. Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A & Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2001 86 732-737.
36. Cantürk Z, Cetinarslan B, Tarkun I, Cantürk NZ, Ozden M & Duman C. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2003 13 971-977.
37. Özcan MA, Çömlekçi A, Demrkan F, Yüksel F, Sari I, Demir T, Ozsan GH, Orük G, Yeşil S & Undar B. Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders. Thrombosis Research 2003 110 243-247.
38. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J & Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Annals of Internal Medicine 2008 148 832-845.
39. Farid NR, Griffiths BL, Collins JR, Marshall WH & Ingram DW. Blood coagulation and fibrinolysis in thyroid disease. Thrombosis and Haemostasis 1976 35 415-422.
40. Marongiu F, Conti M, Murtas ML, Mameli G, Sorano GG & Martino E. What causes the increase in platelet mean volume in thyroid pathological conditions? Thrombosis and Haemostasis 1990 63 323-324.
41. Erem C, Ersöz H, Karti SS, Ukinç K, Hacihasanoglu A, Deǧer O & Telatar M. Blood coagulation and fibrinolysis hyperthyroidism. Journal of Endocrinological Investigation 2002 25 345-350.
42. Hymes K, Blum M, Lackner H & Karpatkin S. Easy bruising, thrombocytopenia, and elevated platelet immunoglobulin G in Graves' disease and Hashimoto's thyroiditis. Annals of Internal Medicine 1981 94 27-30.
43. Marshall JS, Weisberger AS & Levy RP. Coexistent idiopathic thrombocytopenic purpura and hyperthyroidism. Annals of Internal Medicine 1967 67 411-414.
44. Adrouny A, Sandler R & Carmel R. Variable presentation of thrombocytopenia in Graves' disease. Archives of Internal Medicine 1982 142 1460-1464.
45. Pinals RS, Tomar RH, Haas DC & Farah F. Graves' disease, myasthenia gravis and purpura. Annals of Internal Medicine 1977 87 250.
46. Yamaguchi K, Ookubo Y, Matsuda H, Suzaki K, Fujushima H & Uzwa H. Idiopathic thrombocytopenic purpura subsequent to Graves' disease and insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice 1987 3 233-237.
47. Hofbauer LC, Spitzweg C, Schmauss S & Heufelder AE. Graves disease associated with autoimmune thrombocytopenic purpura. Archives of Internal Medicine 1997 157 1033-1036.
48. Cordiano I, Betterle C, Spadaccino CA, Soini B, Girolami A & Fabris F. Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes? Clinical and Experimental Immunology 1998 113 373-378.
49. Franchini M, Lippi G, Manzato F & Vescovi PP. Thyroid-associated autoimmune coagulation disorders. Journal of Thrombosis and Thrombolysis 2010 29 87-91.
50. Marongiu F, Conti M, Murtas ML, Sorano GG, Mameli G, Salis G, Mathieu A & Martino E. Anti-cardiolipin antibodies in Grave's disease: relationship with thrombin activity in vivo. Thrombosis Research 1991 64 745-749.
51. Paggi A, Caccavo D, Ferri GM, Di Prima MA, Amorosa A, Vaccaro F, Bonomo L & Afeltra A. Anticardiolipin antibodies in autoimmune thyroid disease. Clinical Endocrinology 1994 40 329-333.
52. Hofbauer LC, Spitzweg C & Heufelder AE. Graves' disease associated with the primary antiphospholipid syndrome. Journal of Rheumatology 1996 23 1435-1437.
53. Takahashi A, Tamura A & Ishikawa O. Antiphospholipid antibody syndrome complicated by Graves' disease. Journal of Dermatology 2002 29 776-780.
54. Homoncik M, Gessl A, Ferlitsch A, Jilma B & Vierhapper H. Altered platelet plug formation in hyperthyroidism and hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2007 92 3006-3012.
55. Loeliger EA & Esch B. The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism and during fever. Thrombosis et Diathesis Haemorrhagica 1963 10 267-277.
56. Rogers JS & Shane SR. Factor VIII activity in normal volunteers receiving oral thyroid hormone. Journal of Laboratory and Clinical Medicine 1983 102 444-449.
57. Lippi G, Franchini M, Targher G, Montagnana M, Salvagno GL, Guidi GC & Favaloro EJ. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. Journal of Thrombosis and Thrombolysis 2009 28 362-365.
58. Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clinical Endocrinology 2006 64 323-329.
59. Morishita E, Hashimoto T, Asakura H, Saito M, Yamazaki M, Aoshima K, Yoshida T, Kato H & Matsuda T. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease. Thrombosis and Haemostasis 1998 79 919-923.
60. Chadarevian R, Bruckert E, Giral P & Turpin G. Relationship between thyroid hormones and fibrinogen levels. Blood Coagulation & Fibrinolysis 1999 10 481-486.
61. Diez JJ & Iglesias P. Pulmonary thromboembolism after inferior petrosal sinus sampling in Cushing's syndrome. Clinical Endocrinology 1997 46 775-777.
62. Obuobie K, Davies JS, Ogunko A & Scanlon MF. Venous thromboembolism following inferior petrosal sinus sampling in Cushing's disease. Journal of Endocrinological Investigation 2000 23 542-544.
63. La Brocca A, Terzolo M, Pia A, Paccotti P, De Giuli P & Angeli A. Recurrent thromboembolism as a hallmark of Cushing's syndrome. Journal of Endocrinological Investigation 1997 20 211-214.
64. Small M, Lowe GD, Forbes CD & Thomson JA. Thromboembolic complications in Cushing's syndrome. Clinical Endocrinology 1983 19 503-511.
65. Yoshimura S, Ago T, Kitazono T, Yonekura T, Kumai Y, Kuroda J, Kamouchi M, Ooboshi H, Ibayashi S & Iida M. Cerebral sinus thrombosis in a patient with Cushing's syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 2005 76 1182-1183.
66. Sjoberg HE, Blombäck M & Granberg PO. Thromboembolic complications, heparin treatment in increase in coagulation factors in Cushing's syndrome. Acta Medica Scandinavica 1976 199 95-98.
67. Mancini T, Kola B, Mantero F, Boscaro M & Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology 2004 61 768-777.
68. Etxabe J & Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clinical Endocrinology 1994 40 479-484.
69. Oikarinen A, Hoythya M & Jarvinen M. Dexamethasoneinduced plasminogen activator inhibitor: characterization, purification and preparation of monoclonal anti-bodies. Archives of Dermatological Research 1990 282 153-158.
70. Laug WE. Glucocorticoids inhibit plasminogen activator production by endothelial cells. Thrombosis and Haemostasis 1983 50 888-892.
71. Barouski-Miller A & Gelehrter TD. Paradoxical effects of glucocorticoids on regulation of plasminogen activator activity of rat hepatoma cells. PNAS 1982 79 2319-2322.
72. Jacoby R, Owings J, Ortega T, Gosselin R & Feldman E. Biochemical basis for the hypercoagulable state seen in Cushing syndrome. Archives of Surgery 2001 136 1003-1007.
73. Fatti LM, Bottasso B, Invitti C, Coppola R, Invitti F & Mannucci PM. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. Journal of Endocrinological Investigation 2000 23 145-150.
74. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M & Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagulation & Fibrinolysis 1992 3 789-793.
75. Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Salek SZ, Jelcic J, Aganovic I & Korsic M. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009 36 70-74.
76. Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O & Onder Ersoz H. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. Journal of Endocrinological Investigation 2009 32 169-174.
77. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S & Girolami A. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagulation & Fibrinolysis 1999 10 145-151.
78. Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S & Girolami A. Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thrombosis and Haemostasis 1985 54 518-520.
79. Ambrosi B, Sartorio A, Pizzocaro A, Passini E, Bottasso B & Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Experimental and Clinical Endocrinology & Diabetes 2000 108 294-298.
80. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM & Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 3663-3666.
81. Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, Lip GY, Reddy S & Kickler TS. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thrombosis Research 2006 118 247-252.
82. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, Gerdes VE, Büller HR & Brandjes DP. Hypercoagulable state in Cushing's syndrome: a systematic review. Journal of Clinical Endocrinology and Metabolism 2009 94 2743-2750.
83. Sacca L, Napoli R & Cittadini A. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clinical Endocrinology 2003 59 660-671.
84. Wildbrett J, Hanefeld M, Fü cker K, Pinzer T, Bergmann S, Siegert G & Breidert M. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Experimental and Clinical Endocrinology & Diabetes 1997 105 331-335.
85. Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G & Arosio M. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Experimental and Clinical Endocrinology & Diabetes 2000 108 486-492.
86. Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L & Bengtsson BA. Elevated fibrinogen levels decrease following treatment of acromegaly. Clinical Endocrinology 1997 46 69-74.
87. Delaroudis SP, Efstathiadou ZA, Koukoulis GN, Kita MD, Farmakiotis D, Dara OG, Goulis DG, Makedou A, Makris P, Slavakis A & Avramides AI. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clinical Endocrinology 2008 69 279-284.
88. Rosen T & Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288.
89. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357 425-431.
90. Elhadd TA, Abdu TA & Clayton R. Hypopituitarism and atherosclerosis. Annals of Medicine 2001 33 477-485.
91. Elhadd TA, Abdu TA, Oxtoby J, Kennedy G, McLaren M, Neary R, Belch JJ & Clayton RN. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. Journal of Clinical Endocrinology and Metabolism 2001 86 4223-4232.
92. Johansson JO, Landin K, Tengborn L, Rosén T & Bengtsson BA. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arteriosclerosis, Thrombosis, and Vascular Biology 1994 14 434-437.
93. Johansson JO, Landin K, Johannsson G, Tengborn L & Bengtsson BA. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thrombosis and Haemostasis 1996 76 422-428.
94. Kvasnicka J, Marek J, Kvasnicka T, Weiss V, Marková M, Stěpán J & Umlaufová A. Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clinical Endocrinology 2000 52 543-548.
95. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P & Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 1999 84 453-457.
96. Gomez JM, Sahún M, Vila R, Domènech P, Catalina P, Soler J & Badimón L. Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency. Clinical Endocrinology 2006 64 632-639.
97. Miljic D, Miljic P, Doknic M, Pekic S, Djurovic M, Colovic M & Popovic V. Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient adults. Hormones 2006 5 187-191.
98. Wallaschofski H, Kobsar A, Sokolova O, Eigenthaler M & Lohmann T. Co-activation of platelets by prolactin or leptin - pathophysiological findings and clinical implications. Hormone and Metabolic Research 2004 36 1-6.
99. Wallaschofski H, Donné M, Eigenthaler M, Hentschel B, Faber R, Stepan H, Koksch M & Lohmann T. PRL as a novel potent cofactor for platelet aggregation. Journal of Clinical Endocrinology and Metabolism 2001 86 5912-5919.
100. Wallaschofski H, Kobsar A, Koksch M, Siegemund A, Hentschel B, Tuschy U, Lohmann T, Sokolova O & Eigenthaler M. Prolactin receptor signaling during platelet activation. Hormone and Metabolic Research 2003 35 228-235.
101. Wallaschofski H, Lohmann T, Hild E, Kobsar A, Siegemund A, Spilcke-Liss E, Hentschel B, Stumpf C, Daniel WG, Garlichs CD & Eigenthaler M. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thrombosis and Haemostasis 2006 96 38-44.
102. Raaz D, Wallaschofski H, Stumpf C, Yilmaz A, Cicha I, Klinghammer L, Daniel WG, Lohmann T & Garlichs CD. Increased prolactin in acute coronary syndromes as putative co-activator of ADP-stimulated P-selectin expression. Hormone and Metabolic Research 2006 38 767-772.
103. Norman RJ, Dewailly D, Legro RS & Hickey TE. Polycystic ovary syndrome. Lancet 2007 370 685-697.
104. Meyer C, McGrath BP & Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 2005 90 5711-5716.
105. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF & Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 2562-2568.
106. Wild S, Pierpoint T, McKeigue P & Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology 2000 52 595-600.
107. Yildiz BO, Haznedaroglu IC, Kirazli S & Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. Journal of Clinical Endocrinology and Metabolism 2002 87 3871-3875.
108. Kelly CJ, Lyall H, Petrie JR, Gould GW, Connell JM, Rumley A, Lowe GD & Sattar N. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 3287-3290.
109. Atiomo WU, Bates SA, Condon JE, Shaw S,West JH & Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertility and Sterility 1998 69 236-241.
110. Erdoǧan M, Karadeniz M, Alper GE, Tamsel S, Uluer H, Caǧlayan O, Saygili F & Yilmaz C. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Experimental and Clinical Endocrinology & Diabetes 2008 116 143-147.
111. Adali E, Yildizhan R, Kurdoglu M, Bugdayci G, Kolusari A & Sahin HG. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome. Fertility and Sterility 2009. In Press. DOI: 10.1016/ j.fertnstert.2009.03.037.
112. Orio F Jr, Palomba S, Cascella T, Tauchmanovà L, Nardo LG, Di Biase S, Labella D, Russo T, Savastano S, Tolino A, Zullo F, Colao A & Lombardi G. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reproductive Biomedicine Online 2004 9 505-510.
113. Lind L, Jacobsson S, Palmér M, Lithell H,Wengle B & Ljunghall S. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. Journal of Internal Medicine 1991 230 29-35.
114. Lundgren E, Lind L, Palmér M, Jakobsson S, Ljunghall S & Rastad J. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 2001 130 978-985.
115. Hedbäck G & Odén A. Persistent disease after surgery for primary hyperparathyroidism: the long-term outcome. European Journal of Endocrinology 2004 150 19-25.
116. Erem C, Kocak M, Nuhoglu I, Yilmaz M & Ucuncu O. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. European Journal of Endocrinology 2009 160 863-868.
117. Erem C, Kocak M, Hacihasanoglu A, Yilamaz M, Saglam F & Ersoz HO. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels. Experimental and Clinical Endocrinology & Diabetes 2008 116 619-624.
118. Chertok-Shacham E, Ishay A, Lavi I & Luboshitzky R. Biomarkers of hypercoagulability and inflammation in primary hyperparathyroidism. Medical Science Monitor 2008 14 628-632.
119. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H & Eckel RH. The metabolic syndrome. Endocrine Reviews 2008 29 777-822.
120. Franchini M, Targher G, Montagnana M & Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis. Thrombosis Research 2008 122 727-735.
121. Trost S, Pratley R & Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Current Diabetes Reports 2006 6 47-54.
122. Palomo I, Alarcon M, Moore-Carrasco R & Argiles JM. Hemostasis alterations in metabolic syndrome. International Journal of Molecular Medicine 2006 18 969-974.
123. Mina A, Favaloro EJ & Koutts J. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review. Seminars in Thrombosis and Hemostasis 2007 33 798-809.
124. Alessi MC & Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thrombosis and Haemostasis 2008 99 995-1000.
125. Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodés-Cabau J, Bertrand OF & Poirier P. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 1039-1049.
126. Li H & Forstermann U. Nitric oxide in the pathogenesis of vascular disease. Journal of Pathology 2000 190 244-254.
127. Bonetti PO, Lerman LO & Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 168-175.
128. Kim JA, Montagnani M, Koh KK & Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006 113 1888-1904.
129. Shoelson SE, Lee J & Goldfine AB. Inflammation and insulin resistance. Journal of Clinical Investigation 2006 116 1793-1801.
130. Van Gaal LF, Mertens IL & De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006 444 875-880.
131. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL & Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation 2003 112 1796-1808.
132. Nieuwdorp M, Stroes ES, Meijers JC & Bü ller H. Hypercoagulability in the metabolic syndrome. Current Opinion in Pharmacology 2005 5 155-159.
133. Anfossi G, Russo I & Trovati M. Platelet dysfunction in central obesity. Nutrition, Metabolism, and Cardiovascular Diseases 2009 19 440-419.
134. Randriamboavonjy V & Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. Diabetes Care 2009 32 528-530.
135. Olufadi R & Byrne CD. Effects of VLDL and remnant particles on platelets. Pathophysiology of Haemostasis and Thrombosis 2006 35 281-291.
136. Fay WP, Garg N & Sunkar M. Vascular functions of the plasminogen activation system. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1231-1237.
137. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW & Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002 106 2442-2447.
138. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabetic Medicine 2007 24 1-6.
139. Kotronen A & Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 27-38.
140. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I & Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Seminars in Thrombosis and Hemostasis 2009 35 277-287.
141. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M & Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity 2008 16 1394-1399.
142. Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I & Alessi MC. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. Journal of Thrombosis and Haemostasis 2003 1 791-797.
143. Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, Roka R, Minar E & Schernthaner G. Weight loss reduces tissue factor in morbidly obese patients. Obesity Research 2003 11 950-956.
144. Mills JD, Mansfield MW & Grant PJ. Factor XIII-circulating levels and the Va134Leu polymorphism in the healthy male relatives of patients with severe coronary artery disease. Thrombosis and Haemostasis 2002 87 409-414.
145. Targher G, Bonadonna RC, Alberiche M, Zenere MB, Muggeo M & Bonora E. Relationship between soluble adhesion molecules and insulin sensitivity in type 2 diabetic individuals. Role of adipose tissue. Diabetes Care 2001 24 1961-1966.
146. Arteaga RB, Chirinos JA, Soriano AO, Jy W, Horstman L, Jimenez JJ, Mendez A, Ferreira A, de Marchena E & Ahn YS. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. American Journal of Cardiology 2006 98 70-74.
147. Morange PE, Renucci JF, Charles MA, Aillaud MF, Giraud F, Grimaux M & Juhan-Vague I. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thrombosis and Haemostasis 2001 85 999-1003.
148. Klein I & Ojamaa K. Thyroid hormone and the cardiovascular system. New England Journal of Medicine 2001 344 501-509.
149. Hennekens CH, Dyken ML & Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997 96 2751-2753.
150. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association & National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 2735-2752.